Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending February 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific insider transaction disclosures and does not contain comprehensive financial statements.
Material Changes and Transactions
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) on February 13, 2015, resulting from the revaluation of the cash element within the GSK 401K plan. The transaction occurred at a price of $47.94 per ADS.
- Dr M M Slaoui (Director/PDMR): 18 ADSs
- Dr K Slaoui (Connected Person): 4 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director share allocations.
Key Facts for Investor Verification
- Verify the impact of the GSK 401K plan revaluation on director holdings as of February 13, 2015.
- Confirm the transaction price of $47.94 per ADS aligns with market data for that date.
- Note that this filing does not contain operational or financial performance data for the period.